MA46771A - Méthode de traitement de tumeur immunothérapeutique - Google Patents
Méthode de traitement de tumeur immunothérapeutiqueInfo
- Publication number
- MA46771A MA46771A MA046771A MA46771A MA46771A MA 46771 A MA46771 A MA 46771A MA 046771 A MA046771 A MA 046771A MA 46771 A MA46771 A MA 46771A MA 46771 A MA46771 A MA 46771A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment method
- tumor treatment
- immunotherapeutic
- immunotherapeutic tumor
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420442P | 2016-11-10 | 2016-11-10 | |
| US201762582852P | 2017-11-07 | 2017-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46771A true MA46771A (fr) | 2021-06-02 |
Family
ID=62110016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046771A MA46771A (fr) | 2016-11-10 | 2017-11-09 | Méthode de traitement de tumeur immunothérapeutique |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190275133A1 (fr) |
| EP (1) | EP3538130A4 (fr) |
| JP (1) | JP2019534308A (fr) |
| KR (1) | KR20190105568A (fr) |
| CN (1) | CN109890406A (fr) |
| AU (1) | AU2017357042A1 (fr) |
| CA (1) | CA3043597A1 (fr) |
| IL (1) | IL266511A (fr) |
| MA (1) | MA46771A (fr) |
| MX (1) | MX2019005465A (fr) |
| WO (1) | WO2018089669A2 (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (fr) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Immunotolérance ciblée |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| WO2019094396A1 (fr) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Polyimmunothérapies pour le traitement du cancer |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2020176797A1 (fr) * | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Association d'immunothérapies pour le traitement du cancer |
| EP3934680A4 (fr) * | 2019-03-08 | 2022-12-07 | Cend Therapeutics, Inc. | Cytokine à faible dose co-administrée avec irgd pour le traitement du cancer |
| US12351653B1 (en) | 2019-03-08 | 2025-07-08 | Lisata Therapeutics, Inc. | Pharmaceutical compositions comprising novel cyclic peptides |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| EP4107187A4 (fr) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | Immunotolérance ciblée sur un tissu avec un effecteur cd39 |
| CN115997008A (zh) | 2020-04-22 | 2023-04-21 | 艾欧凡斯生物治疗公司 | 协调用于患者特异性免疫疗法的细胞的制造的系统和方法 |
| CA3177413A1 (fr) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection de lymphocytes t reactifs a une tumeur ameliores |
| CA3176826A1 (fr) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Procedes de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunotherapie |
| WO2022010928A1 (fr) * | 2020-07-06 | 2022-01-13 | Nektar Therapeutics (India) Pvt. Ltd. | Méthode d'amélioration de l'immunité humorale |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| WO2022076606A1 (fr) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs |
| EP4259164A1 (fr) | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Traitement de patients atteints de cancer par des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de braf et/ou des inhibiteurs de mek |
| AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| EP4262827A1 (fr) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Traitement de cancers à l'aide de lymphocytes infiltrant les tumeurs |
| JP2024501845A (ja) | 2020-12-31 | 2024-01-16 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス |
| WO2022165260A1 (fr) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Procédés de fabrication de lymphocytes infiltrant les tumeurs modifiés et leur utilisation dans la thérapie cellulaire adoptive |
| EP4301138A2 (fr) | 2021-03-05 | 2024-01-10 | Iovance Biotherapeutics, Inc. | Stockage de tumeur et compositions de culture cellulaire |
| US20240191191A1 (en) | 2021-03-19 | 2024-06-13 | Iovance Biotherapeutics, Inc. | Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| CA3215830A1 (fr) | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Recepteurs costimulateurs chimeriques, recepteurs de chimiokines et leur utilisation dans des immunotherapies cellulaires |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| EP4373270A2 (fr) | 2021-07-22 | 2024-05-29 | Iovance Biotherapeutics, Inc. | Procédé de cryoconservation de fragments de tumeur solide |
| JP2024527961A (ja) | 2021-07-28 | 2024-07-26 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療 |
| WO2023039488A1 (fr) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Procédés de production de produits til par inactivation de pd-1 avec talen |
| US20250000903A1 (en) | 2021-09-24 | 2025-01-02 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (fr) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systèmes et méthodes pour coordonner la fabrication de cellules pour l'immunothérapie spécifique d'un patient |
| CA3237410A1 (fr) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Procedes de traitement de multiplication utilisant des lymphocytes infiltrant les tumeurs cd8 |
| EP4469065A1 (fr) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine |
| CA3243416A1 (fr) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Lymphocytes d’infiltration de tumeur modifiés pour exprimer des charges utiles |
| WO2023196877A1 (fr) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| CA3251533A1 (fr) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Traitement de patients atteints d'un cancer avec des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un agoniste d'il-15r |
| WO2024011114A1 (fr) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Dispositifs et procédés de production automatisée de lymphocytes infiltrant les tumeurs |
| US20260021181A1 (en) | 2022-08-01 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583890A1 (fr) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Procédés de génération de produits til à l'aide d'une double inactivation talen de pd-1/tigit |
| EP4583889A1 (fr) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Procédés de génération de produits til à l'aide d'une double inactivation de talen pd-1/tigit |
| EP4612277A1 (fr) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Procédés d'expansion de lymphocytes infiltrant les tumeurs (til) liés à la sélection de cd39/cd103 |
| JP2025539816A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法 |
| WO2024118836A1 (fr) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie |
| WO2025015318A2 (fr) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Vecteurs lentiviraux codant poru des cytokines et leurs utilisations pour la fabrication de lymphocytes infiltrant les tumeurs |
| WO2025019790A1 (fr) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Traitement de patients atteints d'un cancer avec des thérapies par lymphocytes infiltrant les tumeurs en combinaison avec un adc ciblant trop-2 |
| WO2025054540A1 (fr) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Procédés d'édition génique à l'aide de nucléases programmables |
| WO2025101484A1 (fr) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Traitement de cancers endométriaux avec des thérapies lymphocytaires infiltrant les tumeurs |
| WO2025171182A1 (fr) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Traitement de patients atteints d'un cancer au moyen de thérapies par lymphocytes infiltrant les tumeurs en combinaison avec un vaccin contre le cancer |
| WO2026006784A1 (fr) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Procédés de fabrication de lymphocytes de sang périphérique réactifs aux tumeurs (trpbl) |
| WO2026035866A1 (fr) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Traitement de patients atteints d'un cancer par des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un inhibiteur de lag-3 et un inhibiteur de pd-1 |
| WO2026072794A2 (fr) | 2024-09-26 | 2026-04-02 | Iovance Biotherapeutics, Inc. | Procédés d'expansion pour produit de til enrichi en lymphocytes t réactifs aux néoantigène (nart) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| CN101573139A (zh) * | 2006-02-16 | 2009-11-04 | 纳森特生物制剂公司 | 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法 |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012065086A1 (fr) * | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugués d'une fraction il-2 et d'un polymère |
| WO2013130102A2 (fr) * | 2012-03-02 | 2013-09-06 | Providence Health & Services - Oregon | Bithérapie anticancéreuse basée sur l'agoniste ox40/il-2 |
| US20150017120A1 (en) * | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| KR102410090B1 (ko) * | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| WO2016025647A1 (fr) * | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un vaccin contre le cancer |
-
2017
- 2017-11-09 KR KR1020197015656A patent/KR20190105568A/ko not_active Ceased
- 2017-11-09 EP EP17870172.8A patent/EP3538130A4/fr not_active Withdrawn
- 2017-11-09 MA MA046771A patent/MA46771A/fr unknown
- 2017-11-09 CA CA3043597A patent/CA3043597A1/fr not_active Abandoned
- 2017-11-09 US US16/349,227 patent/US20190275133A1/en not_active Abandoned
- 2017-11-09 JP JP2019524428A patent/JP2019534308A/ja active Pending
- 2017-11-09 WO PCT/US2017/060911 patent/WO2018089669A2/fr not_active Ceased
- 2017-11-09 CN CN201780067219.5A patent/CN109890406A/zh active Pending
- 2017-11-09 AU AU2017357042A patent/AU2017357042A1/en not_active Abandoned
- 2017-11-09 MX MX2019005465A patent/MX2019005465A/es unknown
-
2019
- 2019-05-07 IL IL266511A patent/IL266511A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190105568A (ko) | 2019-09-17 |
| IL266511A (en) | 2019-07-31 |
| US20190275133A1 (en) | 2019-09-12 |
| CA3043597A1 (fr) | 2018-05-17 |
| EP3538130A2 (fr) | 2019-09-18 |
| EP3538130A4 (fr) | 2020-06-03 |
| WO2018089669A2 (fr) | 2018-05-17 |
| MX2019005465A (es) | 2019-10-02 |
| WO2018089669A3 (fr) | 2018-06-28 |
| JP2019534308A (ja) | 2019-11-28 |
| AU2017357042A1 (en) | 2019-05-30 |
| CN109890406A (zh) | 2019-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46771A (fr) | Méthode de traitement de tumeur immunothérapeutique | |
| IL283838A (en) | Method of treating cancer with a cancer therapy in combination with another therapeutic agent | |
| IL296080B1 (en) | Method for treating cancer | |
| IL269026A (en) | Methods of treating tumor | |
| PL3288581T3 (pl) | Sposób leczenia nowotworu | |
| IL255261A0 (en) | Methods for treating cancer | |
| IL256025A (en) | Methods of diagnosing and treating cancer | |
| MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| MA48862A (fr) | Méthode de traitement de tumeur immunothérapeutique | |
| EP3820461A4 (fr) | Méthode de traitement du cancer | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| PT3265087T (pt) | Método de tratamento com tradipitant | |
| EP3389634A4 (fr) | Méthodes de traitement du cancer | |
| HUE049511T2 (hu) | Módszer magok stimulálására | |
| MA47408A (fr) | Traitement du cancer | |
| EP3606531A4 (fr) | Méthodes de traitement du cancer | |
| EP3375440A4 (fr) | Méthode de traitement de la mucosite | |
| MA45780A (fr) | Méthodes de traitement du cancer de la prostate | |
| EP3375108A4 (fr) | Traitement dewlan | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| PL3408417T3 (pl) | Sposób obróbki cieplnej | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3389652A4 (fr) | Méthodes de traitement du cancer |